Guardant Health (GH) concentration risks

The company's disclosed concentration profile is anchored by a large product-revenue skew, with smaller customer dependencies layered beneath it. Tests — the company's core genomic testing services — accounted for 94% of revenue in 2025, a large share by disclosed size that is structural in character. This reflects a business that is fundamentally a testing company: revenue is almost entirely derived from the interpretation and reporting of genomic assays rather than from adjacent services or products. The practical implication is that any disruption to reimbursement coverage, clinical adoption, or competitive positioning for the test menu would affect nearly the entirety of the revenue base. Within the remaining customer mix, two smaller dependencies are disclosed. Revenue from the top five biopharmaceutical customers, including affiliated entities, accounted for 11% of total revenue in 2025 — a small share by disclosed size — and revenue attributable to Medicare exceeded 10% of total revenue, also a small share by disclosed size with a dependency character. Both payer and pharma-partnership revenue streams are subject to coverage policy changes and contract renewal dynamics, respectively, which adds a modest idiosyncratic layer on top of the structural product concentration. On balance, the dominant watch variable is the stability of the reimbursement and clinical adoption environment for the core test portfolio, with payer coverage policy — particularly Medicare — and biopharma partnership retention as secondary but relevant considerations.

For the engine’s reasoning on GH’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.